Business
Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors
- Biopharma executive and oncology physician-scientist with extensive experience in early and late clinical development with successful track record leading
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"- Biopharma executive and oncology physician-scientist with extensive experience in early and late clinical development with successful track record leading development of multiple oncology products from strategic planning through global submissions and approvals\n\n\nHOUSTON, March 1, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the appointment of Joy Yan, M.D., Ph.D. to its Board of Directors. \n\n \n \n \n \n \n \n\n \n\"We are incredibly pleased to welcome Dr. Yan to our Board of Directors. Her leadership and expertise in building, executing, and advancing clinical programs with major players in the pharma industry will be a valuable perspective as we work to progress our portfolio of drug candidates,\" added Walter Klemp, Chairman and CEO of Moleculin Biotech.\nDr. Yan added, \"I am excited to join the Moleculin Board of Directors and provide guidance to help position the Company for continued growth. This committed management team has made great accomplishments. I believe that Moleculin's pipeline and science will propel the Company to its next development phase and build value for stakeholders.\"\nJoy Yan, M.D., Ph.D., currently serves as an Independent Board Director at Checkmate Pharmaceuticals. She is also a member of the Scientific Advisory Board at Ambrx, after her role as the Chief Medical Officer, where she led the pipeline strategy and quickly advanced the development programs. She also assisted on the cross-over financing and IPO. Previously at Bristol Myers Squibb, she led the successful development of multiple oncology products from strategic planning through global submissions and approvals, including BMS' first FDA Pilot Programs (RTOR, Project ORBIS, AAid) for nivolumab and ipilimumab. She also has broad clinical development experience from her roles with Janssen and Bayer, where she led Phase 1, 2 and 3 studies exploring a variety of MOAs and evaluated NMEs (daratumumab, radium-223, anti-IL3R, Bi-specifics, ADCs, TKIs) across multiple tumor types. \nDr. Yan completed her Ph.D. in Biochemistry & Molecular Biology at Johns Hopkins University. She received her M.D. from China Medical University and completed her resi...